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esses: charlotte.ruse@sSummary We aimed to examine the role of tumour necrosis factor gene complex
polymorphisms in subjects with chronic obstructive pulmonary disease (COPD). We
hypothesized that individuals possessing polymorphic variants associated with higher
tumour necrosis factor (TNF) secretion would be more susceptible to and/or have
more severe disease.
Patients with COPD and population controls underwent detailed clinical
phenotyping. Genotyping for the tumour necrosis factor-308 and the lymphotoxin
alpha NcoI (LTa polymorphisms was carried out by ‘blinded’ laboratory staff. Three
hundred and sixty one individuals (220 cases and 141 controls) were recruited. We
showed an association between the LTaNcol polymorphism and forced vital capacity
(FVC) in a population of older adults with and without COPD. The LTaNcol*2 allele
was associated with poorer lung function, under a codominant model, with a fall in
FVC (expressed as a percentage of its predicted value) of 3.7% for each copy of the
LTaNcol*2 allele possessed (for FVC, regression coefficient (95% CI) ¼ 3.73(7.01
to 0.44), P ¼ 0.026; for FEV1 regression coefficient ¼ 3.56(7.80 to 0.70),
P ¼ 0.101. However, there was no difference in genotype distribution between the
case and control populations.Elsevier Ltd. All rights reserved.
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Tumour necrosis factor polymorphisms in COPD 341This study adds weight to the suggestion that the TNF gene complex is involved in
physiological alterations (FVC) that may affect the development and severity of
COPD. The absence of a significant association between the TNF gene-complex
polymorphisms in this study does not rule out a modest effect of these
polymorphisms on the risk of COPD, as much larger studies are needed to detect
modest gene effects on binary disease endpoints.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a
common condition with significant morbidity and
mortality.1,2 Smoking is a key environmental risk
factor, but there is a marked difference in
individual susceptibility to developing COPD.3
There are a large number of possible candidate
genes for COPD pathogenesis, but to date there is
little evidence available from linkage studies that
can reliably guide the selection of these candidate
genes.4,5 The selection of candidate genes for
association studies in COPD has therefore focused
on a number of polymorphisms in apparent central
roles in disease pathogenesis. One of these is the
tumour necrosis factor (TNF) gene complex on
chromosome 6p.
One key candidate gene has emerged, a poly-
morphism of the tumour necrosis factor-308
polymorphism (TNF -308). A closely linked poly-
morphism of the lymphotoxin alpha promotor has
also been widely studied.
The TNF-308 polymorphism is a biallelic restric-
tion fragment length polymorphism (RFLP) origin-
ally described by Wilson.6 The less common
TNF308*2 allele has been associated with higher
baseline and induced expression of TNF-a.7 Thus
this variant might be expected to be associated
with increased severity of disease or possibly
increased susceptibility to COPD.
The Ncol polymorphism lies in the first intron of
the lymphotoxin alpha gene and is also biallelic It is
debated if the Ncol polymorphism is of any
functional significance, but there is some evidence
that the LTa Ncol*2 allele is associated with higher
TNFa levels.8,9
Several studies have examined the role of both of
these polymorphisms, particularly the -308 poly-
morphism, in subjects with COPD.10–13
Our primary hypotheses were that these poly-
morphisms determined susceptibility to COPD and/
or severity of COPD, by quantitative effects on the
pulmonary function. Specifically we hypothesised
that the polymorphisms have modifying effects on
FEV1 and FVC.Study population
Subjects with COPD all had airflow obstruction
(FEV1/FVC ratio o70% and FEV1o80% of its
predicted value). All cases had a smoking history
of at least 10 pack-years and symptom onset after
45 years of age. Controls were recruited from
general practitioner patient lists and were age, sex
and geographically matched with cases. The con-
trols had no history of respiratory disease and
normal spirometry. All subjects were Caucasian.
The study was approved by two local research
ethics committees and participants gave written
informed consent.Genotyping
DNA was extracted from whole blood using a DNA
extraction system (Gentra, PURGENE DNA purifica-
tion kit). Genotyping was performed for the
lymphotoxin alpha polymorphism and the TNF
polymophism adapted from previously published
protocols.6,14Statistical methodology
Contingency table analysis using the w2 test was
used to determine if the polymorphisms had any
effects on disease susceptibility. The quantitative
primary outcome variables were FEV1 and FVC,
both expressed as a percentage of their predicted
values based on European Community Coal and
Steel tables. The quantitative variables were
examined using multiple regression analysis, with
age, sex and smoking history examined as covari-
ates in all regression models.
Data was analysed using SPSS version 10.0 and
STATA 7.0. Statistical significance defined as
Po0.05. Power calculations were based upon a
sample size of 200 cases and 200 controls. This is
sufficient to detect a difference between propor-
tions of, for example, 11% and 2% for the
LTaNcol1,1 genotype (a ¼ 0.05, b ¼ 0.2). These
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in magnitude to those reported in younger asth-
matic populations.Results
Two hundred and twenty cases and 141 controls
were genotyped for the lymphotoxin alpha Ncol and
TNF-308 polymorphisms. Other data from these
subjects (with others) have been previously pre-
sented.15
Demographic data for the case and control
populations is summarized in Table 1.
The case and control populations were in Hardy–
Weinberg Equilibrium. Allele frequencies for LTaN-
col allele 1 were 0.33 and for TNF-308 allele 2 were
0.15. The two polymorphisms lay in strong linkage
disequilibrium (w2 ¼ 151, Po0.001).
There was no difference in genotype distribution
between the case and control populations for
either of the polymorphism.Table 1 Characteristics of the case and control populat
Cases (number ¼ 220)
Mean age (SD) 67.4 (9.9)
Gender (% male) 59.1%
Percentage
ever:ex:current smokers
0:70:30
Median pack-year
history (interquartile
range)
30–40 pack years,
(20–30 pack-years-
50–60 pack-years)
Mean FEV1 (SD) 46.6 (19.3)
Mean FVC (SD) 76.5 (21.4)
Table 2 Relationship between genotypes and primary
controls).
Genotype (number of
subjects)
Mean FEV1
(SD)
Mean FVC
(SD)
Ge
sub
TNF-308 1,1 (251) 64.0 (30.2) 84.4 (22.7) LTa
TNF-308 1,2 (97) 66.7 (28.5) 86.3 (21.6) LTa
TNF-308 2,2 (10) 62.6 (27.6) 82.5 (21.1) LTa
Linear regression
model: Regression
coefficient (95% CI); Py
P ¼ 0.610 P ¼ 0.614
Age, sex and smoking history included as covariates in all reg
yAdditive codominant model equivalent to a ‘per-allele’ dosagOur primary hypothesis was that the polymorph-
ism might have an effect on pulmonary function.
Table 2 shows the relationship between mean FEV1
and mean FVC, by genotype for the study popula-
tion. A significant trend in FVC (P ¼ 0.026) was seen
across the LTA genotypes with an average fall of
3.7% in FVC for each additional copy of the
LTaNcol*2 allele (Table 2). A similar trend was
observed in cases alone (Table 3) A non-significant
(P ¼ 0.101) trend was also evident in FEV1 across
the LTA genotypes (Table 2). The effect of the TNF-
308 allele 2 polymorphism on either FVC or FEV1
was less clear.Discussion
In this study, the frequencies of the LTaNcol
polymorphism and the TNF-308 polymorphism are
the same order of magnitude as reported in other
recent studies involving Western Caucasian popula-
tions.16–18ions.
Controls
(number ¼ 141)
Statistical summary
68.5 (8.5) t-test ¼ 1.12,
P ¼ 0.263
58.9% w2 ¼ 0.002, P ¼ 0.966
30:52:18 w2 ¼ 75.3, Pp0.005
10–20 pack years, (0
pack years-30–40 pack
years)
w2 test for trend ¼ 144,
Po0.005
93.3 (16.3) t-test ¼ 22.9,
Po0.005
97.7 (16.8) t-test ¼ 9.9, Po0.005
outcome variables for study population (cases and
notype (number of
jects)
Mean FEV1 (SD)0 Mean FVC
(SD)
2,2 (158) 62.0 (30.3) 82.3 (23.0)
1,2 (161) 66.7 (30.1) 86.1 (22.4)
1,1 (42) 68.7 (24.7) 89.7 (17.9)
b ¼ 3.56
(7.80–0.70),
P ¼ 0.101
b ¼ 3.73
(7.01 to
0.44),
P ¼ 0.026
ression models.
e effect.
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Table 3 Relationship between LTa genotype and pulmonary function for subjects with COPD.
Genotype (number of
cases)
Mean FEV1 (SD) Mean FVC (SD) Mean KCO (SD)

LTa 2,2 (71) 43.8 (19.2) 73.7 (21.8) 80.1 (28.7)
LTa 1,2 (73) 48.1 (19.8) 77.1 (20.9) 82.5 (26.7)
LTa 1,1 (15) 52.8 (15.7) 86.0 (19.7) 78.3 (27.3)
Regression coefficient,
significance
b ¼ 3.04, P ¼ 0.106 b ¼ 4.25, P ¼ 0.051 b ¼ 0.51, P ¼ 0.881
Data based on 159 subjects.
Tumour necrosis factor polymorphisms in COPD 343We have shown an association between the
LTaNcol polymorphism and FVC in a population of
older adults with and without COPD. The LTaNcol*2
allele was associated with poorer lung function.
From a pathobiological perspective one would
predict that the LTaNcol*2 allele would be asso-
ciated with more severe disease. It is possible that
being homozygous for the rare allele may accel-
erate inflammatory processes, in the presence of
cigarette smoke.
Importantly, the regression model explained only
a moderate proportion of the variability of FVC and
FEV1 suggesting that additional factors determining
pulmonary function in this population and these are
likely to be a combination of genetic and environ-
mental influences.
We have not found that these polymorphisms
determine the susceptibility to COPD.
In summary, the TNF gene-complex polymorph-
ism LTaNcol appears to play a role in determining
FVC, and may therefore also influence the devel-
opment of COPD. However, much larger studies
(probably in the region of 5000 cases) are required
to detect the modest effects of genes on binary
disease endpoints. The failure to detect an associa-
tion between TNF gene-complex polymorphisms in
our study would not rule out a modest effect of
these polymorphisms on the risk of COPD. Although
we tested only two genetic polymorphisms in this
study, the results of any genetic association study
should be interpreted with appropriate caution,
since multiple testing may lead to ‘‘false-positive’’
associations,19 However, in the context of the
overall evidence available for the involvement of
genes in this pathway in the development of COPD,
there is sufficient evidence to suggest that the TNF
gene complex polymorphisms appear to modify
lung function in older adult smokers, in our study.
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